Cadila Healthcare is currently trading at Rs. 405.90, up by 1.25 points or 0.31% from its previous closing of Rs. 404.65 on the BSE.
The scrip opened at Rs. 405.95 and has touched a high and low of Rs. 409.30 and Rs. 403.50 respectively. So far 14258 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 373.05 on 06-Feb-2018.
Last one week high and low of the scrip stood at Rs. 410.50 and Rs. 397.00 respectively. The current market cap of the company is Rs. 41466.69 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.93% and 8.28% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Dexmedetomidine Hydrochloride Injection 200 mcg (base)/ 2 mL (100 mcg (base) /mL) single-dose vials.
The drug is indicated for sedation of intubated and mechanically ventilated patients during treatment in an intensive care setting and for sedation of non-intubated patients prior to and/or during surgical and other procedures. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
